Literature DB >> 12958612

Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness.

Nils Kucher1, Verena Schroeder, Hans P Kohler.   

Abstract

In patients with acute pulmonary embolism (PE), pulmonary occlusion rate is directly related to D-dimer and inversely related to fibrinogen levels. The role of coagulation factor XIII (FXIII) levels in acute venous thromboembolism is not known. A total of 120 consecutive patients with suspected PE and VIDAS D-dimer levels >500 micro g/L were investigated by helical computed tomography (CT). Pulmonary occlusion rate was assessed by CT using the modified Miller index. D-dimer, fibrinogen, and FXIII A- and B-subunit antigen levels were taken on admission. Thrombelastography (TEG) was performed in a subset of patients (n = 12). The 71 patients with PE had lower FXIII A-subunit levels than the 49 patients with excluded PE (78.6 +/- 24.5% vs. 91.3+/-28.8%, p=0.01). In both groups, FXIII A-subunit was inversely related to D-dimer levels. FXIII A-subunit correlated with fibrinogen levels in patients with PE but not in patients without PE. FXIII A-subunit decreased with increasing pulmonary occlusion rate. The risk of PE was increased in the presence of A-subunit levels < 60% (OR 7.0 [95% CI 1.4-35.3], p = 0.019). Clot firmness determined by TEG was lower in patients with PE than in patients without PE. In patients with PE, circulating FXIII A-subunit is decreased compared to patients with suspected but excluded PE. The higher the clot burden within the pulmonary arteries the lower the FXIII antigen. In these patients, direct relation of FXIII A-subunit to fibrinogen levels argues for significant consumption of these coagulation factors in PE. This consumption of FXIII can also be detected by a global coagulation test like TEG.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958612     DOI: 10.1160/TH03-07-0031

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.

Authors:  Sravya Kattula; Yaqiu Sang; Gustaaf de Ridder; Anna C Silver; Emma G Bouck; Brian C Cooley; Alisa S Wolberg
Journal:  J Thromb Haemost       Date:  2021-09-06       Impact factor: 5.824

2.  Nitrated fibrinogen is a biomarker of oxidative stress in venous thromboembolism.

Authors:  Marissa Martinez; Adam Cuker; Angela Mills; Richard Lightfoot; Yiying Fan; W H Wilson Tang; Stanley L Hazen; Harry Ischiropoulos
Journal:  Free Radic Biol Med       Date:  2012-05-10       Impact factor: 7.376

3.  Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort.

Authors:  Mark M G Mulder; LIoyd Brandts; Renée A G Brüggemann; Marcel Koelmann; Alexander S Streng; Renske H Olie; Hester A Gietema; Henri M H Spronk; Iwan C C van der Horst; Jan-Willem E M Sels; Joachim E Wildberger; Sander M J van Kuijk; Ronny M Schnabel; Hugo Ten Cate; Yvonne M C Henskens; Bas C T van Bussel
Journal:  Thromb J       Date:  2021-05-31

Review 4.  Advances of Coagulation Factor XIII.

Authors:  Da-Yu Shi; Shu-Jie Wang
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

Review 5.  Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism.

Authors:  Michał Ząbczyk; Joanna Natorska; Anetta Undas
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

6.  Coagulation Factor XIII Subunit A Is a Biomarker for Curative Effects and Prognosis in Malignant Solid Tumors, Especially Non-small Cell Lung Cancer.

Authors:  Yujiao Luo; Bin Li; Ji Li; Yang Zhang; Mingyang Deng; Chunhong Hu; Wenzhe Yan; Zhiguang Zhou; Guangsen Zhang
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

7.  Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5.

Authors:  Huriye Ercan; Waltraud Cornelia Schrottmaier; Anita Pirabe; Anna Schmuckenschlager; David Pereyra; Jonas Santol; Erich Pawelka; Marianna T Traugott; Christian Schörgenhofer; Tamara Seitz; Mario Karolyi; Jae-Won Yang; Bernd Jilma; Alexander Zoufaly; Alice Assinger; Maria Zellner
Journal:  Front Cardiovasc Med       Date:  2021-11-11

8.  Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower-leg injury or knee arthroscopy.

Authors:  Yassene Mohammed; Carolina E Touw; Banne Nemeth; Raymond A van Adrichem; Christoph H Borchers; Frits R Rosendaal; Bart J van Vlijmen; Suzanne C Cannegieter
Journal:  J Thromb Haemost       Date:  2022-01-06       Impact factor: 16.036

9.  F13A1 Gene Variant (V34L) and Residual Circulating FXIIIA Levels Predict Short- and Long-Term Mortality in Acute Myocardial Infarction after Coronary Angioplasty.

Authors:  Lucia Ansani; Jlenia Marchesini; Gabriele Pestelli; Giovanni Andrea Luisi; Giulia Scillitani; Giovanna Longo; Daniela Milani; Maria Luisa Serino; Veronica Tisato; Donato Gemmati
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

10.  Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observation studies.

Authors:  Marina Panova-Noeva; Bianca Wagner; Markus Nagler; Thomas Koeck; Vincent Ten Cate; Jürgen H Prochaska; Stefan Heitmeier; Imke Meyer; Christoph Gerdes; Volker Laux; Stavros Konstantinides; Henri M Spronk; Thomas Münzel; Karl J Lackner; Kirsten Leineweber; Hugo Ten Cate; Philipp S Wild
Journal:  EBioMedicine       Date:  2020-09-10       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.